Elder Care

Experimental antiplatelet compound for acute stroke shows promise

An experimental compound inhibited clot formation without increased bleeding, a common side effect of current anticlotting therapies, in a phase I study. First-in-human study shows the anticlotting drug was well-tolerated without serious safety concerns in healthy volunteers. Next-phases will gauge effectiveness and safety in patients with acute ischemic strokes.

Related posts

Mice regrow brain tissue after stroke with bioengineered gel


PTSD alone didn’t increase heart disease risk in veterans with PTSD


In MS, disintegrating brain lesions may indicate the disease is getting worse